A maleimide-functionalized Pt-MSA-2 derivative formed stable albumin adducts, translating into promising in vivo pharmacokinetic profiles with strongly enhanced plasma levels and tumor platinum accumulation in CT-26 tumor-bearing mice in comparison with oxaliplatin and the reference non-maleimide complex. This evidence concerns the gene ALB and neoplasm.